Synonym
Fozivudine tidoxil; BM-211290; FZT; HDP-99.0002; HDP-990002; W-09726867
IUPAC/Chemical Name
((2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl ((R)-2-(decyloxy)-3-(dodecylthio)propyl) hydrogen (R)-phosphate
InChi Key
IBHARWXWOCPXCR-VBWFMVIDSA-N
InChi Code
InChI=1S/C35H64N5O8PS/c1-4-6-8-10-12-14-15-17-19-21-23-50-28-30(45-22-20-18-16-13-11-9-7-5-2)26-46-49(43,44)47-27-32-31(38-39-36)24-33(48-32)40-25-29(3)34(41)37-35(40)42/h25,30-33H,4-24,26-28H2,1-3H3,(H,43,44)(H,37,41,42)/t30-,31+,32-,33-/m1/s1
SMILES Code
O=[P@](OC[C@@H](OCCCCCCCCCC)CSCCCCCCCCCCCC)(OC[C@H]1O[C@@H](N(C(N2)=O)C=C(C)C2=O)C[C@@H]1N=[N+]=[N-])O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
745.96
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Miller MM, Fogle JE. Administration of Fozivudine tidoxil as a single-agent therapeutic during acute feline immunodeficiency virus infection does not alter chronic infection. Viruses. 2012 Jun;4(6):954-62. doi: 10.3390/v4060954. PubMed PMID: 22816034; PubMed Central PMCID: PMC3397356.
2: Fogle JE, Tompkins WA, Campbell B, Sumner D, Tompkins MB. Fozivudine tidoxil as single-agent therapy decreases plasma and cell-associated viremia during acute feline immunodeficiency virus infection. J Vet Intern Med. 2011 May-Jun;25(3):413-8. doi: 10.1111/j.1939-1676.2011.0699.x. PubMed PMID: 21457319; PubMed Central PMCID: PMC3785110.
3: Venhoff AC, Lebrecht D, Reuss FU, Heckl-Ostreicher B, Wehr R, Walker UA, Venhoff N. Mitochondrial DNA depletion in rat liver induced by fosalvudine tidoxil, a novel nucleoside reverse transcriptase inhibitor prodrug. Antimicrob Agents Chemother. 2009 Jul;53(7):2748-51. doi: 10.1128/AAC.00364-09. PubMed PMID: 19433557; PubMed Central PMCID: PMC2704664.
4: Fozivudine: BM 211290, fozivudine tidoxil, FZT, HDP 990002, W 09726867. Drugs R D. 2004;5(1):41-3. Review. PubMed PMID: 14725491.
5: Bogner JR, Roecken M, Herrmann DB, Boerner D, Kaufmann B, Gürtler L, Plewig G, Goebel FD. Phase I/II trial with fozivudine tidoxil (BM 21.1290): a 7 day randomized, placebo-controlled dose-escalating trial. Antivir Ther. 1997 Dec;2(4):257-64. PubMed PMID: 11327445.
6: Bogner JR, Boerner D, Mühlhöfer A, Thoma-Greber E, Herrmann DB, Hoegl L, Roecken M, Jost V, Goebel FD. Single dose, dose-escalating trial with fozivudine tidoxil (BM 21.1290). Antivir Ther. 1997 Dec;2(4):249-56. PubMed PMID: 11327444.
7: Girard PM, Pegram PS, Diquet B, Anderson R, Raffi F, Tubiana R, Sereni D, Boerner D. Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. J Acquir Immune Defic Syndr. 2000 Mar 1;23(3):227-35. PubMed PMID: 10839658.
